Table 3.
Summary of recent clinical trials using MSCs for cerebral palsy.
| Reference | Disease | Source | Number | Mean Age (Range), Year | Route of Administration | Number of Cells | Number of Treatments | Results | Adverse Events | |
|---|---|---|---|---|---|---|---|---|---|---|
| Trial | Control | |||||||||
| Gu et al. [67] | Cerebral palsy (Phase 1/2) |
UC | 19 | 20 | 4.29 | IV | 4.5–5.5 × 107 cells at 7-day intervals |
4 | Gross motor and comprehensive functional recovery and improvement in the ADL after 3, 6, 12 months | No |
| Ahn et al. [68] | Intraventricular hemorrhage (Phase 1) |
UCB | 9 | 0 | 11.6 (7–15) (days) |
Intraventricular | 5 × 106/kg or 1 × 107/kg |
1 | Only safety assessment | No |
| Huang et al. [65] | Cerebral palsy (Phase 1/2) |
UCB | 27 | 27 | 7.4 (3–12) |
IV | 5 × 107 cells at 7-day intervals | 4 | Gross motor and comprehensive functional recovery after 3, 6, 12, 24 months | No |
| Liu et al. [66] | Cerebral palsy (Phase 1/2) |
BM | MSC 33 MNC34 |
35 | 7–132 (months) |
IT | 1 × 106/kg at 3–4-day intervals | 4 | Motor functional recovery after 12 months | No |
| Wang et al. [69] | Cerebral palsy (Phase 4) |
UC | 16 (8 twins) | 0 | 6.29 (3–12) |
IT | 1–2 × 106 cells at 3–5-day intervals | 4 | Motor functional recovery after 1 and 6 months | No |
| Wang X et al. [70] | Cerebral palsy | BM | 46 | 0 | 6–180 (months) |
IT Intra-Parenchymal |
2 × 107 cells 4 × 107 cells at 5-day intervals |
2 + 1 or 4 |
Gross motor functional recovery after 1, 6, 18 months | No |
IV, intravenous injection; IT, intrathecal injection; BM, bone marrow; UC, umbilical cord; UCB, umbilical cord blood.